La cadena de opciones muestra datos clave de las opciones de acciones de Treace Medical Concepts a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Treace Medical Concepts..

Treace Medical Concepts (NASDAQ:TMCI) Bolsa, Cadena de Opciones

Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATPC

BDMD

CGBS

CRKN

DWTX

New Oriental Education & Technology Group

ELTX

EONR

FFWM

GOEV

IROQ

ORKT

RSKD

RYAM

SWKH

TMCI

TPET

TTGT

VATE

Descubre las acciones que lideran el premercado con sorprendentes subidas y caídas. INNOVATE y más protagonistas hoy.

Las acciones de INNOVATE (VATE) cotizan un 19% más alto; 20 acciones que se mueven en el premercado de EE.UU.

ALVO

BBGI

BCAX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts Inc

<a href="https://www.globenewswire.com/Tracker?data=UYBRPwD_JxPY7Mv8Z3CmTaoUDFWJ_7K_49cmCLIKdDwm0g-NfND5wCph-3dE_8uvp-Sn_fmAx2u5hQP_00S6cPoifPVbdJG4smcvVT5uPUY=">Netcapital Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>, NCPLW))) (the "Company"), a digital private capital markets ecosystem, today announced that Matt Morgan has joined the Company's newly established Crypto Advisory Board.
A seasoned advisor to multiple blockchain ventures, Matt Morgan currently serves as an advisor to World Liberty Financial, a decentralized finance (DeFi) initiative backed by Donald Trump. He brings extensive expertise in digital asset strategy, decentralized systems, and the evolving regulatory landscape.
Morgan joins an accomplished group of industry leaders on the Crypto Advisory Board, including Kyle Klemmer, Josh Meier, Eric Galen, Armondo Soto, and Noah Holmes.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

NCPL

Netcapital Establishes Crypto Advisory Board And Appoints Blockchain Strategist Matt Morgan, Advisor To World Liberty Financial

Volato Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) shares are trading higher Thursday after the company announced a strategic move to acquire M2i Global, a developer of <a href="https://www.benzinga.com/pressreleases/25/06/b45901740/volato-to-combine-with-m2i-global-in-a-strategic-transaction-unlocking-value-through-industrial-sc">critical mineral supply chains</a>.
What To Know: The deal, detailed in a newly signed non-binding term sheet, will transition Volato from a pure-play aviation company into a dual-platform business with exposure to both aviation software and U.S. critical minerals infrastructure.
Under the terms of the transaction, M2i Global will receive approximately 90% of Volato's common stock on a fully diluted basis, while current Volato shareholders will retain around 10%. The combined entity will be led by Alberto Rosende as CEO, with current Volato CEO Matt Liotta becoming president of the aviation and software division.
The move positions Volato to benefit from federal policies focused on U.S. mineral independence, leveraging M2i's high-value contracts, including an $850 million offtake agreement with NT Minerals. It also preserves Volato's core aviation platforms like Vaunt and Mission Control, which will continue operating under dedicated leadership.
The market responded positively to the announcement, viewing it as a way for Volato to unlock new capital access and scale through diversification, while aligning with national strategic priorities. The deal is pending customary closing conditions.
SOAR Price Action: Volato shares were up 4.15% at $2.26 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45910248/stock-market-flat-dollar-inflation-data-thursday">Stocks Flat, Dollar Sinks To Over 2-Year Lows After Inflation Data: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image Via Shutterstock.

SOAR

What's Going On With Volato Group Shares Today?

LIMN

Liminatus Pharma Shares Halted On Circuit Breaker To The Upside, Stock Now Up 110.4%

WIIM

VYGR

VYGR stock has given up its prior loss. Voyager Technologies shares were trading lower. The stock may be pulling back after its recent post-IPO surge.

Windtree Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares have trended lower over the past two trading sessions following a strong surge in shares on Tuesday. Here&#8217;s a look at <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45862900/windtree-stock-is-rising-tuesday-whats-going-on">what&#8217;s going on</a>.
What To Know: Windtree Therapeutics stock spiked well above $1.00 on Tuesday after the company announced a binding agreement to acquire waste management company Titan Environmental Services.
Windtree said it believes the fragmented waste management market provides an opportunity to scale the business and provide growth for the company. Titan Environmental Services will become Windtree Environmental Services upon closing of the transaction, which is expected in the third quarter.
&#8220;This transaction strategically aligns with our vision of diversifying our business model by increasing revenue and providing significant growth potential for the Company,&#8221; said Jed Latkin, CEO of Windtree.
The strong surge in shares was short-lived as the stock pulled back to around 65 cents, but shares got a boost again on Wednesday after the company announced that it received a non-binding letter of intent to purchase its preclinical oncology aPKCi inhibitor platform for $7 million. The offer also included up to $130 million in milestone payments, as well as royalties of up to $1.5 billion. 
Despite climbing back up to around 85 cents Wednesday morning, Windtree shares again trended lower for most of the session and weakness has continued into Thursday with the stock down another 12.6%, trading at approximately 61 cents at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Windtree had just $1.2 million in cash and cash equivalents as of March 31. The company announced this week that it raised an additional $3.9 million through note purchase agreements. 
The significant volatility in Windtree is expected given the company&#8217;s market cap of just $2.56 million and low float of just 3.66 million shares. Low-float micro-cap stocks tend to be extremely volatile.
Windtree Therapeutics shares are down approximately 96.5% year-to-date, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45910248/stock-market-flat-dollar-inflation-data-thursday">Stocks Flat, Dollar Sinks To Over 2-Year Lows After Inflation Data: What&#8217;s Driving Markets Thursday?</a></li>
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45912081/simulations-plus-slashes-guidance-amid-biotech-spending-cuts-analyst-expresses-doubt">Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt</a></li>
</ul>
This illustration was generated using artificial intelligence via MidJourney.

WINT

Windtree Therapeutics Stock Is Volatile This Week: What's Going On?

Newly public Tvardi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) is capturing investor attention following its recent reverse merger with Cara Therapeutics, Inc.
In April, the company completed its&nbsp;previously announced&nbsp;merger with Cara Therapeutics. Tvardi is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies targeting STAT3 to treat <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">fibrosis-driven diseases</a>.
STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44825819/tvardi-therapeutics-announces-closing-of-merger-with-cara-therapeutics" rel="noreferrer noopener">and immune suppression</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45730076/trevi-therapeutics-showcases-drug-that-cuts-cough-frequency-in-lung-disease-patients" rel="noreferrer noopener">Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients</a>
With the initial merger announcement, Tvardi completed a previously announced private placement financing of approximately $28 million from a syndicate of new and existing institutional investors.
Its lead candidate, TTI-101, is in a Phase 2 trial for idiopathic pulmonary fibrosis (IPF) and a Phase 1b/2 trial for hepatocellular carcinoma (HCC).&nbsp;
With Tvardi&#8217;s existing cash and approximately $24 million of Cara cash at closing, Tvardi is expected to have sufficient cash to fund its operating expenses and capital expenditure requirements, as currently planned, into the second half of 2026, including through its two anticipated Phase 2 data readouts.
On Thursday, Piper Sandler initiated coverage on Tvardi Therapeutics. &#8220;TTI-101 is positioned to drive broad improvement with an optimal profile,&#8221; analyst Yasmeen Rahimi said.
Rahimi mentioned that TTI-101 is a differentiated small molecule that inhibits STAT3 nuclear function but has no impact on non-canonical STAT3 mitochondrial function (given non-covalent bonding).
Thus, TTI-101 is uniquely positioned to drive meaningful anti-fibrotic effects for IPF at cellular and immune levels, given STAT3&#8217;s broad effects on clotting/coagulation, inflammatory cell migration, fibroblast proliferation, and ECM deposition (vs. typical therapies only targeting one aspect), the analyst asserted.
Piper has initiated an Overweight rating <a target="_blank" href="https://www.benzinga.com/quote/TVRD/analyst-ratings" rel="noreferrer noopener">with a price forecast of $78</a>, with an upside of over 150%.
TTI-101 is also de-risked with robust preclinical evidence showing lung fibrosis reduction and stat sig oxygen saturation improvements, Rahimi pointed out.
Further, the analyst highlighted that TVRD is also developing TTI-109 (a next-gen STAT3 inhibitor) with optimized delivery, enhanced patent protection, and an IND filed in June 2025.
Price Action: TVRD stock is trading higher by 2.56% to $26.89 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/03/44088147/pliant-therapeutics-stock-sinks-discontinues-mid-stage-study-for-lung-disorder" target="_blank" rel="noreferrer noopener">Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Health Care

Price Target

Initiation

Analyst Ratings

General

TVRD

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

https://www.americanexpress.com/en-us/newsroom/articles/innovation/new-coinbase-one-card-to-launch-on-the-american-express-network.html#:~:text=Today%2C%20at%20Coinbase's%20State%20of,issued%20by%20First%20Electronic%20Bank.

COIN

'New Coinbase One Card to Launch on the American Express Network'

Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) shares are trading higher Thursday ahead of the company's fiscal second-quarter earnings report, with investor focus centering on AI integration, <a href="https://www.benzinga.com/quote/ADBE/earnings">product growth and forward guidance</a>.
What To Know: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45906998/adobe-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-4">Wall Street expects Adobe</a> to report revenue of $5.79 billion and earnings per share of $4.96, both reflecting significant year-over-year growth. The company's own guidance falls within the expected range. 
Analysts are also looking closely at Adobe's AI monetization strategy, particularly through products like Firefly and Acrobat. Despite frequent earnings beats in the past, Adobe shares have dropped after six of the last seven quarterly reports, partly due to conservative forward-looking guidance.
Adobe's stock remains under pressure, down 6.8% year-to-date and about 35% below its all-time high. Freedom Capital's Jay Woods <a href="https://www.benzinga.com/trading-ideas/previews/25/06/45891931/adobe-q2-earnings-preview-expert-says-guidance-ai-progress-important-after-being-nothing-but-a-heartache-for-investors">emphasized</a> that investors will be watching for signs of accelerating annual recurring revenue tied to AI tools, and whether the company can boost sentiment with its guidance.
Separately, Adobe announced a <a href="https://www.benzinga.com/pressreleases/25/06/b45903431/newell-brands-embraces-adobe-firefly-and-adobe-express-to-power-its-content-supply-chain-with-gene">new partnership with Newell Brands</a> ahead of the report, to integrate Adobe's generative AI tools, including Firefly and Adobe Express, to scale digital content creation. Newell reported improved efficiency in packaging design and social content production, with generative AI shortening turnaround times and boosting productivity. The partnership highlights Adobe's role in the enterprise AI ecosystem and reinforces its strategy to expand AI-powered services across industries.
Investor attention remains high going into Thursday's report, as Adobe's ability to meet or exceed expectations and issue strong guidance will likely determine its short-term stock trajectory.
ADBE Price Action: Adobe shares were up 0.43% at $414.57 at the time of publication Thursday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45910248/stock-market-flat-dollar-inflation-data-thursday">Stocks Flat, Dollar Sinks To Over 2-Year Lows After Inflation Data: What&#8217;s Driving Markets Thursday? </a></li>
</ul>
Image Via Shutterstock.

ADBE

What's Going On With Adobe Stock Thursday?

Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) just pulled off a classic chartist's dream &#8211; <a href="https://www.benzinga.com/topic/golden-cross">the Golden Cross</a> &#8211; and the bulls are charging. On June 11, the stock's 50-day simple moving average (SMA) climbed above its 200-day SMA, signaling a long-term bullish trend.
The very next day, Microsoft stock punched through resistance to hit a record high of $478.78, building on a three-month gain of 23% and crushing the S&amp;P 500's modest advance in the same period.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612"><img loading="lazy" decoding="async" width="628" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12125117/Screenshot-2025-06-12-at-8.35.48-PM.png" alt="" class="wp-image-947978" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12125117/Screenshot-2025-06-12-at-8.35.48-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12125117/Screenshot-2025-06-12-at-8.35.48-PM-300x232.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0612" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Momentum Overload: Technicals Flash Bullish &#8211; With A Caveat</h2>
Microsoft stock price is now well above its five, 20 and 50-day exponential moving averages, a strongly bullish signal. The current share price of $477.32 also trades above its eight-day SMA of $469.81, 20-day SMA of $461.98 and 50-day SMA of $423.84 &#8211; each flashing continued upside potential. 
Even the long-term 200-day SMA at $419.25 is far behind, reinforcing that Microsoft's momentum hasn't just taken off &#8211; it's soaring.
The Moving Average Convergence Divergence (MACD) is at 12.80, with a recent bullish crossover. However, momentum may be softening a touch—MACD histogram bars have ticked lower for three consecutive sessions. Meanwhile, the Relative Strength Index (RSI) is at an overheated 76.77, suggesting overbought territory.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/45900050/chatgpt-kept-begging-to-restart-before-being-beaten-by-1979-atari-2600-in-a-beginner-level-chess-showdown">ChatGPT Kept &#8216;Begging To Restart&#8217; Before Being Beaten By 1979 Atari 2600 In A &#8216;Beginner Level&#8217; Chess Showdown</a>
<h2 class="wp-block-heading">AI Muscle Keeps Fundamentals Strong</h2>
Microsoft's technical strength is being matched step by step by its fundamentals. Third-quarter earnings, reported on April 30, delivered a 16.5% post-earnings surge, with revenue and earnings per share comfortably beating expectations. The Intelligent Cloud segment continues to fire on all cylinders, powered by Azure's AI capabilities and tight integration with OpenAI's models.
Enterprise adoption of Copilot, growth in Microsoft 365, and strong performance from LinkedIn are reinforcing Microsoft&#8217;s sticky revenue streams. A quarterly dividend of $0.83 per share was announced on June 10, underscoring the company's financial confidence.
Add to that Microsoft's Pentagon-linked AI copilot development and a dominant market cap position alongside Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and it's no wonder analysts have an average target as high as $517.93.
<h2 class="wp-block-heading">Trend Is Bullish, But Don't Ignore The Heat</h2>
A breakout fueled by a Golden Cross, surging institutional buying, and tech leadership in AI and cloud all point to continued strength in Microsoft stock. 
But with RSI flashing red and MACD losing a bit of steam, a short-term dip to digest gains wouldn&#8217;t be a surprise. In the long term, though, Microsoft seems to still have altitude left on this flight path.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45910211/trumps-first-six-months-these-4-markets-crush-sp-500-as-tariffs-boomerang">Trump&#8217;s First Six Months: These 4 Markets Crush S&amp;P 500 As Tariffs Boomerang</a></li>
</ul>

Long Ideas

Tech

AAPL

MSFT

NVDA

Microsoft's Golden Cross Ignites Breakout Rally - But Is A Cooldown Coming?

STLA

TSLA

Reuters Reports, U.S. Commerce Dept Says New Procedures For U.S. Auto Makers To Apply For Offsets To Section 232 Tariffs Applied On Imported Automobile Parts; U.S. Auto Makers Can Apply For Offsets To Section 232 Tariffs Applied On Imported Automobile Parts Based On Volume And Value Of Manufacturers' Automobile Production In U.S.

Deep-pocketed investors have adopted a bullish approach towards Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ANF usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Abercrombie &amp; Fitch. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 0% bearish. Among these notable options, 2 are puts, totaling $71,700, and 6 are calls, amounting to $311,081.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $85.0 for Abercrombie &amp; Fitch over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Abercrombie &amp; Fitch's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Abercrombie &amp; Fitch's significant trades, within a strike price range of $50.0 to $85.0, over the past month.
<h3>Abercrombie &amp; Fitch Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749754908_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$11.7</td>
<td>$11.7</td>
<td>$11.7</td>
<td>$70.00</td>
<td>$117.0K</td>
<td align="right">742</td>
<td align="right">246</td>
</tr>
<tr>
<td>ANF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$38.6</td>
<td>$37.3</td>
<td>$38.5</td>
<td>$50.00</td>
<td>$46.2K</td>
<td align="right">25</td>
<td align="right">12</td>
</tr>
<tr>
<td>ANF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$38.7</td>
<td>$36.9</td>
<td>$38.17</td>
<td>$50.00</td>
<td>$45.8K</td>
<td align="right">25</td>
<td align="right">12</td>
</tr>
<tr>
<td>ANF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$14.9</td>
<td>$14.3</td>
<td>$14.59</td>
<td>$85.00</td>
<td>$43.5K</td>
<td align="right">116</td>
<td align="right">60</td>
</tr>
<tr>
<td>ANF</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/01/25</td>
<td>$5.4</td>
<td>$1.9</td>
<td>$3.6</td>
<td>$73.00</td>
<td>$36.0K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Abercrombie &amp; Fitch</h3>
Abercrombie &amp; Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumers through its stores and websites, which include the Abercrombie &amp; Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Having examined the options trading patterns of Abercrombie &amp; Fitch, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Abercrombie &amp; Fitch Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 954,375, the ANF's price is down by -0.65%, now at $78.5. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>Expert Opinions on Abercrombie &amp; Fitch</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $119.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Abercrombie &amp; Fitch with a target price of $82. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Outperform rating for Abercrombie &amp; Fitch, targeting a price of $125. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Abercrombie &amp; Fitch, which currently sits at a price target of $147. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Abercrombie &amp; Fitch, which currently sits at a price target of $142. 
&#x2A; An analyst from Raymond James has decided to maintain their Outperform rating on Abercrombie &amp; Fitch, which currently sits at a price target of $99. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abercrombie &amp; Fitch with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

This Is What Whales Are Betting On Abercrombie & Fitch

TBBK

The Bancorp shares are trading lower after KBW downgraded the stock from outperform to market perform and lowered its price target from $70 to $65.

Deep-pocketed investors have adopted a bearish approach towards PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PDD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 19 extraordinary options activities for PDD Holdings. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 57% bearish. Among these notable options, 5 are puts, totaling $465,975, and 14 are calls, amounting to $1,190,430.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $140.0 for PDD Holdings, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for PDD Holdings options trades today is 5162.56 with a total volume of 6,705.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for PDD Holdings's big money trades within a strike price range of $80.0 to $140.0 over the last 30 days.
<h3>PDD Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749754903_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$2.1</td>
<td>$2.01</td>
<td>$2.1</td>
<td>$140.00</td>
<td>$420.0K</td>
<td>23.5K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.45</td>
<td>$1.39</td>
<td>$1.4</td>
<td>$105.00</td>
<td>$210.0K</td>
<td>9.2K</td>
<td>1.6K</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.0</td>
<td>$15.9</td>
<td>$15.9</td>
<td>$110.00</td>
<td>$170.1K</td>
<td>5.0K</td>
<td>212</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.8</td>
<td>$15.4</td>
<td>$15.8</td>
<td>$110.00</td>
<td>$158.0K</td>
<td>5.0K</td>
<td>100</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$1.74</td>
<td>$1.73</td>
<td>$1.74</td>
<td>$107.00</td>
<td>$87.7K</td>
<td>78</td>
<td>503</td>
</tr>
</tbody>
</table>

<h3>About PDD Holdings</h3>
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
In light of the recent options history for PDD Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of PDD Holdings</h3>
<ul>
<li>With a trading volume of 3,502,255, the price of PDD is down by -0.06%, reaching $103.1.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>What The Experts Say On PDD Holdings</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $115.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Neutral rating on PDD Holdings with a target price of $105. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on PDD Holdings, which currently sits at a price target of $128. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on PDD Holdings with a target price of $121. 
&#x2A; An analyst from China Renaissance has revised its rating downward to Hold, adjusting the price target to $107. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for PDD Holdings, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

What the Options Market Tells Us About PDD Holdings

Financial giants have made a conspicuous bearish move on Rigetti Computing. Our analysis of options history for Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $98,950, and 8 were calls, valued at $356,972.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $26.0 for Rigetti Computing over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Rigetti Computing's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Rigetti Computing's significant trades, within a strike price range of $7.0 to $26.0, over the past month.
<h3>Rigetti Computing Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749754898_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$1.32</td>
<td>$1.27</td>
<td>$1.27</td>
<td>$12.50</td>
<td>$63.5K</td>
<td>1.3K</td>
<td>1.6K</td>
</tr>
<tr>
<td>RGTI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.69</td>
<td>$15.00</td>
<td>$56.9K</td>
<td>4.3K</td>
<td>101</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.0</td>
<td>$7.1</td>
<td>$8.0</td>
<td>$7.00</td>
<td>$54.4K</td>
<td>3.6K</td>
<td>133</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.0</td>
<td>$7.1</td>
<td>$8.0</td>
<td>$7.00</td>
<td>$52.0K</td>
<td>3.6K</td>
<td>0</td>
</tr>
<tr>
<td>RGTI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$0.5</td>
<td>$0.49</td>
<td>$0.49</td>
<td>$26.00</td>
<td>$46.8K</td>
<td>4.7K</td>
<td>4.9K</td>
</tr>
</tbody>
</table>

<h3>About Rigetti Computing</h3>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.
Following our analysis of the options activities associated with Rigetti Computing, we pivot to a closer look at the company's own performance.
<h3>Where Is Rigetti Computing Standing Right Now?</h3>
<ul>
<li>With a trading volume of 82,597,283, the price of RGTI is up by 0.88%, reaching $12.63.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>Expert Opinions on Rigetti Computing</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $14.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Rigetti Computing with a target price of $15. 
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $14.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Rigetti Computing with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

RGTI

Spotlight on Rigetti Computing: Analyzing the Surge in Options Activity

In the preceding three months, 4 analysts have released ratings for Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.0, a high estimate of $10.00, and a low estimate of $6.00. A 7.69% drop is evident in the current average compared to the previous average price target of $9.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1749754893_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Autolus Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Autolus Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Autolus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Autolus Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AUTL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Autolus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Autolus Therapeutics: A Closer Look</h2>
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 &amp; AUTO8.
<h3>Financial Milestones: Autolus Therapeutics's Journey</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Negative Revenue Trend: Examining Autolus Therapeutics's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -10.99% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Autolus Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -781.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -17.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Autolus Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.18%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.16.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUTL

What 4 Analyst Ratings Have To Say About Autolus Therapeutics

Analysts' ratings for CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $143.5, a high estimate of $170.00, and a low estimate of $129.00. Experiencing a 5.17% decline, the current average is now lower than the previous average price target of $151.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1749754885_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of CBRE Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$131.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$129.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Anthony Paolone</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$141.00</td>
<td>$163.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CBRE Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CBRE Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CBRE Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CBRE Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CBRE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CBRE Group analyst ratings.</a>
<h2>Unveiling the Story Behind CBRE Group</h2>
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
<h3>Breaking Down CBRE Group's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3M period, CBRE Group showcased positive performance, achieving a revenue growth rate of 12.29% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CBRE Group's ROE stands out, surpassing industry averages. With an impressive ROE of 1.95%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.64%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.07.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBRE

Deep Dive Into CBRE Group Stock: Analyst Perspectives (6 Ratings)

Throughout the last three months, 4 analysts have evaluated RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $406.5, with a high estimate of $431.00 and a low estimate of $375.00. This upward trend is apparent, with the current average reflecting a 2.91% increase from the previous average price target of $395.00.
<img src="https://www.benzinga.com/files/images/story/2025/1749754864_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of RBC Bearings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ciarmoli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$431.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Kristine Liwag</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$415.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Michael Ciarmoli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$405.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Michael Ciarmoli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$375.00</td>
<td>$410.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RBC Bearings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RBC Bearings compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of RBC Bearings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into RBC Bearings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RBC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on RBC Bearings analyst ratings.</a>
<h2>Get to Know RBC Bearings Better</h2>
RBC Bearings Inc is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: Industrial, which derives maximum revenue, and Aerospace/Defense. The Aerospace/Defense segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the Industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.
<h3>RBC Bearings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: RBC Bearings displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 5.8%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): RBC Bearings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.44%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.55%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: RBC Bearings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.34.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On RBC Bearings Through 4 Analysts

During the last three months, 28 analysts shared their evaluations of Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">15</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $1199.93, a high estimate of $1514.00, and a low estimate of $1000.00. Observing a 6.07% increase, the current average has risen from the previous average price target of $1131.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1749754842_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Netflix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1425.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$1450.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1250.00</td>
<td>$1020.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$1220.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Vikram Kesavabhotla</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1300.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1380.00</td>
<td>$1200.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$1000.00</td>
<td>$900.00</td>
</tr>
<tr>
<td>Jeffrey Wlodarczak</td>
<td>Pivotal Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$1350.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Mark Mahaney</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1150.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Alicia Reese</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1175.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1070.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1222.00</td>
<td>$1210.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1126.00</td>
<td>$1126.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$1514.00</td>
<td>$1494.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1150.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1200.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1126.00</td>
<td>$1126.00</td>
</tr>
<tr>
<td>John Hodulik</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1140.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Alicia Reese</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1150.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1025.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Michael Morris</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Michael Nathanson</td>
<td>MoffettNathanson</td>
<td>Raises</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$850.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Netflix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Netflix compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Netflix's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Netflix's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NFLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Netflix analyst ratings.</a>
<h2>Discovering Netflix: A Closer Look</h2>
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
<h3>Netflix: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Netflix's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 12.51%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Communication Services sector.
Net Margin: Netflix's net margin is impressive, surpassing industry averages. With a net margin of 27.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Netflix's ROE excels beyond industry benchmarks, reaching 11.85%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Netflix's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.47%, the company showcases efficient use of assets and strong financial health.
Debt Management: Netflix's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.62.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NFLX

28 Analysts Have This To Say About Netflix

Morgan Stanley's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) short percent of float has fallen 15.83% since its last report. The company recently reported that it has 14.30 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Morgan Stanley Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749754831_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Morgan Stanley has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Morgan Stanley's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Morgan Stanley's peer group average for short interest as a percentage of float is 3.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Morgan Stanley?

In the current session, the stock is trading at $111.69, after a 0.79% increase. Over the past month, Oshkosh Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) stock increased by 12.07%, and in the past year, by 5.85%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1749754830_0.png" alt="Past Year Chart" />

<h3>A Look at Oshkosh P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 49.26 in the Machinery industry, Oshkosh Inc. has a lower P/E ratio of 11.84. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749754830_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Oshkosh

Small Cap

Press Releases

TMCI Investors Have Final Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Deadline Soon: Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Legal

Treace Medical Concepts, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – TMCI

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit - TMCI

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical

DEADLINE ALERT for TMCI, IBTA, and NPWR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join – Contact Levi & Korsinsky

Kuehn Law Encourages Investors of Treace Medical Concepts, Inc. to Contact Law Firm

Attention Long-Term Investors of AppLovin Corporation (NASDAQ: APP); Mercury Systems, Inc. (NASDAQ: MRCY); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Treace Medical Concepts, Inc. (NASDAQ: TMCI) – Grabar Law Office is Investigating Claims on Your Behalf!

Attention Long-Term Investors of Manhattan Associates, Inc. (NASDAQ: MANH); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Treace Medical Concepts, Inc. (NASDAQ: TMCI) – Grabar Law Office is Investigating Claims on Your Behalf!

Comments

Treace Medical Concepts

Treace Medical Concepts (TMCI) Opciones

Treace Medical Concepts (NASDAQ:TMCI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL